Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05696977

Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients

Conditions: Nephrotic Syndrome

Sex: All

Ages: 18 Years – N/A

Phase: PHASE4

Enrollment: 74

Sponsor: Alexandria University

Location: Egypt

Summary

This study aims to assess the effect of obesity on therapeutic response and safety of cyclosporine trough level in nephrotic syndrome patients and calculating a suitable weight-based dose.

Eligibility Criteria

Inclusion Criteria:Obese and overweight Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (BMI>25 kg/m2)Normal or underweight individuals Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (serving as control group)Exclusion Criteria:Hepatic patients liver cirrhosis (moderate to severe liver impairment)Cancer patients,Pregnant and lactating female patients

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05696977). StuddyBuddy aggregates publicly available trial information.